Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Bioactivation and Tissue Toxicity

Bioactivation and Tissue Toxicity

Bioactivation is a metabolic process that transforms less reactive substances into highly reactive metabolites, initiating tissue toxicity. This transformation can lead to various toxic effects, including carcinogenesis and teratogenesis. Reactive metabolites are classified into two main types: electrophiles and free radicals.Electrophiles are electron-deficient species and are produced primarily by the enzyme cytochrome P-450 during the metabolism of compounds containing carbon, nitrogen, or...

Drug Biotransformation: Overview

Drug Biotransformation: Overview

Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...

Drug Biotransformation: Overview

Drug Biotransformation: Overview

Biotransformation, also known as drug metabolism, is a vital physiological process that chemically alters drugs, facilitating their elimination from the body and terminating their action. This process involves two main phases: phase I and phase II reactions. Phase I reactions, including oxidation, reduction, and hydrolysis, introduce or unmask polar functional groups on the drug molecule, thereby increasing its water solubility. By enhancing water solubility, the drug becomes more hydrophilic...

Antiepileptic Drugs: GABAergic Pathway Potentiators

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

Antiepileptic Drugs: Glutamate Antagonists

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Evaluation of the biodistribution and preliminary safety profile of a novel brain-targeted manganese dioxide-based nanotheranostic system for Alzheimer's disease.

Nanotoxicology·2024

Same author

Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development.

Journal of autoimmunity·2020

Same author

Real-time imaging of oxidative and nitrosative stress in the liver of live animals for drug-toxicity testing.

Nature biotechnology·2014

Same author

12-OH-nevirapine sulfate, formed in the skin, is responsible for nevirapine-induced skin rash.

Chemical research in toxicology·2013

Same author

In vitro and animal models of drug-induced blood dyscrasias.

Environmental toxicology and pharmacology·2011

Same author

Involvement of T helper 17 cells in D-penicillamine-induced autoimmune disease in Brown Norway rats.

Toxicological sciences : an official journal of the Society of Toxicology·2011

Search research articles

Related Experiment Video

Updated: Jul 15, 2026

Lipidomics and Transcriptomics in Neurological Diseases

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

Possible bioactivation pathways of lamotrigine.

Wei Lu¹, Jack P Uetrecht

¹Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada.

Drug Metabolism and Disposition: the Biological Fate of Chemicals

|April 6, 2007

Summary

Lamotrigine-induced skin rashes may be caused by the parent drug, not reactive metabolites. Studies found limited evidence of metabolic activation, suggesting the drug itself might trigger adverse skin reactions.

Area of Science:

Pharmacology
Toxicology
Drug Metabolism

Background:

Lamotrigine, an anticonvulsant, is linked to idiosyncratic drug reactions, particularly skin rashes.
Reactive metabolites are often implicated in idiosyncratic drug reactions.
Previous research suggested arene oxide formation in rats, but human data and direct binding assays were inconclusive.

Purpose of the Study:

To investigate the metabolic pathways of lamotrigine and identify potential reactive metabolites responsible for idiosyncratic drug reactions, specifically skin rashes.
To assess the role of covalent binding in lamotrigine-induced toxicity.

Main Methods:

Incubation of radiolabeled lamotrigine with rat liver microsomes.
Oxidation of lamotrigine by hypochlorous acid (HOCl) and subsequent adduct formation.

Related Experiment Videos

Last Updated: Jul 15, 2026

Lipidomics and Transcriptomics in Neurological Diseases

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

Incubation with myeloperoxidase/H(2)O(2)/Cl(-) system.

Investigation of N-oxide sulfation using sulfotransferase.

Assessment of oxidation by other peroxidases and enzymes.

Evaluation of lipid peroxidation in vivo.

Main Results:

Minimal covalent binding of lamotrigine to hepatic microsomes was detected; expected phenolic metabolites were not observed in humans.
Lamotrigine was oxidized to N-chloro products by HOCl, with one forming an adduct with N-acetylhistidine.
Covalent binding occurred with myeloperoxidase/H(2)O(2)/Cl(-).
Sulfation of the N-oxide metabolite did not lead to detectable covalent binding.
No evidence of free radical oxidation or increased lipid peroxidation was found.

Conclusions:

The lack of significant covalent binding to hepatic microsomes and absence of other clear metabolic activation pathways suggest the parent lamotrigine molecule, rather than a reactive metabolite, may cause lamotrigine-induced skin rashes.
Further research is needed to elucidate the precise mechanism of lamotrigine-induced skin reactions.